ANAPTYSBIO, INC (ANAB): M&A transaction — AnaptysBio completes spin-off of First Tracks Biotherapeutics (TRAX); distribution effective April 20, 2026

ANAPTYSBIO, INC

Each ANAB shareholder received one TRAX share for each share held on record date April 6, 2026.
First Tracks started trading on Nasdaq under ticker TRAX on April 20, 2026.
AnaptysBio retains royalty management for dostarlimab (Jemperli) and imsidolimab from Vanda.
First Tracks receives $100M cash, up to $35M in Vanda milestones, and clinical assets rosnilimab, ANB033, ANB101.
Separation and Distribution Agreement allocates assets/liabilities between royalty management and biotech businesses.

item 1.01 item 2.01 item 5.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

ANAPTYSBIO, INC completed a disposition involving First Tracks Biotherapeutics, Inc. (closed 2026-04-20).

Action: disposition
Counterparty: First Tracks Biotherapeutics, Inc.
Closing: 2026-04-20

Exact text from the filing

completed the previously announced separation (the "Spin-Off") of First Tracks Biotherapeutics, Inc. ("First Tracks Biotherapeutics") from the Company

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ANAPTYSBIO, INC entered into Separation and Distribution Agreement with First Tracks Biotherapeutics valued at $100.0 million.

Action: entry
Agreement: supply
Counterparty: First Tracks Biotherapeutics
Value: $100.0 million

Exact text from the filing

the Company and First Tracks Biotherapeutics entered into a separation and distribution agreement (the “Separation and Distribution Agreement”)

View on SEC.gov

Browse all m&a transactions →

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001193125-26-164330

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.